Oncology Corporate Profile
IRX Therapeutics' mission is to discover and commercialize drugs that stimulate a coordinated TH1-specific cellular immune response to treat human diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages, and T-cells
|Brand / Product||Class||Area of Study||Phase||Partnership|
|citoplurikin / IRX-2||immunotherapy (stimulant of the TH1-specific cellular immune system)||Head & Neck cancer||II|
|IRX 4-6||immunotherapy||Prostate cancer||Preclinical|
|citoplurikin / IRX-2||immunotherapy (stimulant of the TH1-specific cellular immune system)||Various cancer types||Preclinical|
View additional information on product candidates here »
1/19/2016 12:27 pm
(IRX Therapeutics) Jan 19, 2016 - IRX Therapeutics, a clinical-stage bioresearch company developing cancer immunotherapies, and ImmunID, an immune molecular diagnostics and precision medicine company, today announced they have entered into a collaboration agreement for prediction of response to the IRX-2 immunotherapy candidate using the ImmunTraCkeR® assay.
4/27/2015 11:18 am
(Yahoo! Finance) Apr 27, 2015 - VentiRx Pharmaceuticals, Inc. announced today that the European Commission (EC), acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP), has granted orphan designation to motolimod (formally VTX-2337) as an orphan medicinal product for the treatment of ovarian cancer.
4/7/2015 12:05 pm
(N-of-One) Apr 7, 2015 - N-of-One to enrich molecular profiling results with clinical and scientific evidence and targeted therapy options, initially focused on lung cancer patients, for the Veterans Integrated Service Network 1 (VISN 1) Precision Oncology Program.
9/2/2014 12:07 pm
(Puget Sound Business Journal) Sept 2, 2014 - VentiRx Pharmaceuticals, Inc. today announced that the FDA has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.
4/17/2014 11:54 am
(Reuters) Apr 17, 2014 - VentiRx Pharmaceuticals, Inc. today announced that enrollment has been completed in GOG-3003 (NCT01666444), a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with Pegylated Liposomal Doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy.
10/15/2013 11:59 am
(StreetInsider) Oct 15, 2013 - AirXpanders Inc., a company developing novel technology for women who require tissue expansion for breast reconstruction following a mastectomy, today reported the full results of the PACE-2 (Patient Activated Controlled Expansion) trial of its AeroForm(TM) device.
7/2/2013 11:51 am
(Sacramento Bee) July 2, 2013 - VentiRx Pharmaceuticals, Inc. announced today the initiation of the ACTIVE8 clinical trial, a randomized, placebo-controlled, Phase 2 trial evaluating VTX-2337 in combination with a standard of care regimen, cetuximab, platinum and 5 Fluorouracil (5-FU), in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
10/22/2012 11:36 am
(Sacramento Bee) Oct 22, 2012 - VentiRx Pharmaceuticals, Inc. announced today the initiation of a randomized, placebo-controlled, Phase 2 trial evaluating VTX-2337 in combination with Doxil® (pegylated liposomal doxorubicin) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy.
10/3/2012 12:21 pm
(Xconomy Seattle) Oct 3, 2012 - Celgene is putting some big money into a partnership with Seattle-based VentiRx Pharmaceuticals that aims to go a step further in developing cancer immunotherapies.
10/7/2011 12:24 pm
(MarketWatch) Oct 6, 2011 - Io Therapeutics, Inc. announced today initiation of dosing in a phase II clinical trial with its experimental cancer therapeutic, IRX4204, in patients with advanced prostate cancer.
6/23/2011 12:03 pm
[PR Newswire] - -
10/5/2010 12:00 am
(MarketWatch) Oct 5, 2010 - Immunovaccine Inc. and IRX Therapeutics announced today that the two companies have entered into a preclinical research collaboration to evaluate the combination of IRX's primary cell-derived biologic, IRX-2, and DepoVax(TM) - based therapeutic cancer vaccines.
10/5/2010 12:00 am
(Yahoo! Finance) Oct 4, 2010 - VentiRx Pharmaceuticals, Inc. announced today the successful completion of a Phase 1 clinical study for VTX-2337, its novel TLR8 agonist for oncology at the International Society for Biological Therapy of Cancer (ISBTC).
4/29/2010 12:00 am
(New York dbusiness) April 29, 2010 - IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines.
2/15/2010 07:37 am
Rubberduck Media Lab, a Division of Aspiro and Europe's Leading